Repligen corp stock.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

Repligen Corp’s Stock Price as of Market Close. As of March 03, 2023, 4:00 PM CST, Repligen Corp’s stock price was $188.00. Repligen Corp is up 4.17% from its previous closing price of $180.48. During the last market session, Repligen Corp’s stock traded between $171.57 and $184.29.Successfully navigating the dynamic landscape of stock investing requires an understanding of factors like momentum to judge a stock’s price trend. In this article, we take an in-depth look at Repligen Corp (RGEN) to unravel why momentum evaluation plays a crucial role in making savvy investment choices. We also examine how to measure ...

Find the latest Repligen Corporation (RGN.F) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Repligen Corporation (NASDAQ:RGEN) Q3 ...

RGEN: Repligen Corp Stock Price Quote - NASDAQ GS - Bloomberg Back Forward Markets Data Repligen Corp RGEN:US Nasdaq GS (USD) As of 12:00 AM …CI. Transcript : Repligen Corporation Presents at The Stifel 2023 Annual Healthcare Conference, Nov-15-2023 08:00 AM. Nov. 15. CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07.Oct 20, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 18.68% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

Detailed statistics for Repligen Corporation (RGEN) stock, including valuation metrics, financial numbers, share information and more.

NASDAQ does not use this value to determine compliance with the listing requirements. Repligen Corporation Common Stock (RGEN) Stock Quotes - Nasdaq offers stock quotes & market activity data for ...

Company profile page for Repligen Corp including stock price, company news, press releases, executives, board members, and contact informationRepligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Nov 30, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. Repligen Corp stock has a Value Score of 5, Momentum Score of 54 and Estimate Revisions Score of 37. Comparing Agiliti Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Repligen Corp. Stock , RGEN 157.24 -0.01 -0.00% After-market 04:44:59 PM EDT 11/30/2023 NAS Add to watchlist 157.25 -2.24 -1.40% Official Close 04:00:00 …Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock...

Information on stock, financials, earnings, subsidiaries, investors, and executives for Repligen. Use the PitchBook Platform to explore the full profile. ... Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies an. Biotechnology. Waltham, MA. 2,025 As of 2022 00000000. 000000.Feb 24, 2023 · Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%. UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. Repligen Corp., the recipient of this investment, is a global life sciences company specializing in providing bioprocessing technologies and solutions used in manufacturing biological drugs. ... While Repligen’s stock opened at $156.63 on Friday, the company had a market capitalization of $8.72 billion, with a beta of 1.08, and PE ratio of …Oct 12, 2021 · The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last ... T&C apply*. Buy Repligen Corp Shares from India at $157.25 (0 Commission) today. Start investing in Repligen Corp stocks from India now with fractional investing only on INDmoneyapp.On Friday, Repligen Corp (RGEN:NSQ) closed at 161.78, -19.50% below its 52-week high of 200.98, set on Feb 16, 2023. Data delayed at least 15 minutes, as of Nov 24 2023 18:00 GMT. Latest Repligen Corp (RGEN:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.

Nov 27, 2023 · CI. Transcript : Repligen Corporation Presents at The Stifel 2023 Annual Healthcare Conference, Nov-15-2023 08:00 AM. Nov. 15. CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. × Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGE

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing ...Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.752 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare Steris PLC and Repligen Corp Stock ...Repligen Corp. (RGEN) current stock price is $159.46 with a 24-hour trading volume of 392.47K. The stock decreased by -1.43% in the last 24 hours and rose by +33.35% in the past month. Looking at the chart, RGEN stock price is below the pivot point level of $161.1, suggesting a potential bearish market, if it continues to fall close to the support level of …Apr 25, 2023 · Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today. Feb 22, 2023 · Total revenue as reported for the full year 2022 increased to $801.5 million compared to $670.5 million for the full year 2021, a year-over-year gain of 20%, or 25% at constant currency, overall ... ... Stock quotes by finanzen.net · Home · Stocks · Repligen-stock · News for Repligen Repligen. News for Repligen Corp. GlobeNewswire 20d. UPDATE – Repligen ...Financial Details for the Fourth Quarter and Full Year 2021. Total revenue for the fourth quarter of 2021 increased to $186.5 million compared to $108.6 million for the fourth quarter of 2020, a year-over-year gain of 72% as reported and 73% at constant currency, with organic growth of 69%. Total revenue for the full year 2021 increased to …Repligen Corp stock has a Momentum Score of 57, Estimate Revisions Score of 50 and Quality Score of 73. Comparing DexCom, Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …

... shares relative to the market in the next few months. In addition, Repligen Corporation has a VGM Score of F (this is a weighted average of the individual ...

Nov 9, 2023 · Summary. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. Repligen Corporation to Present at Upcoming Investor Conferences. Nov. 07. AQ. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.Get Repligen Corp (RGEN.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Dec 4, 2023 · × Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGE Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 48.1. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 48.1. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%.Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%.With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of …Feb 28, 2023 · Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%. Analysts expect adjusted earnings to reach $2.678 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare DexCom, Inc. and Repligen Corp Stock ... On October 31, 2023, Repligen Corp (RGEN) reported its latest earnings per share (EPS) of $0.55 and sales of $179.5 million. According to data from CNN Money, 13 analysts have offered their 12-month price forecasts for RGEN. The median target price is $195.00, with a high estimate of $240.00 and a low estimate of $158.00.First quarter 2021 adjusted EPS increased to $0.68 per fully diluted share, compared to $0.32 in the 2020 period, an increase of $0.37, or 116%. Cash and cash equivalents, which are GAAP metrics ...

Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 39 and Quality Score of 71. Comparing Steris PLC and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk ...Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and …Repligen Company Info. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs.Instagram:https://instagram. 70 20 10 budget ruleforex demo tradingbanks that invest your moneywtai holdings 11 brokers have issued 12-month price targets for Repligen's stock. Their RGEN share price targets range from $165.00 to $210.00. On average, they expect the company's … ishares tipsbest bank with mobile app WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch ... arm.stock The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last ...The number of shares of the Company's common stock, $0.01 par value per share ("Common Stock"), entitled to vote at the Annual Meeting was 55,429,107. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 51,525,212, representing 92.96% of the total number of shares of Common …Nov 30, 2023 · The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Repligen Corp. shares valued at $557,328 were sold by Gebski Christine on Nov 10. At $147.13 per share, Gebski Christine sold 3,788 shares.